TruNativ lands $30M Series B from OrbiMed, plots D2C-to-pharmacy push and Gulf entry
Mumbai nutrition brand TruNativ raised $30M Series B led by OrbiMed to scale D2C, quick commerce, modern trade and pharmacy, with UAE and Singapore launches by year-end. FY25 revenue hit ₹125 crore; FY26 target ₹200 crore as it chases share in a $1.62B Indian protein market growing 6.54% CAGR.
Mumbai-based nutrition brand TruNativ raised $30M Series B led by OrbiMed to expand D2C, quick commerce, modern trade and pharmacy distribution, plus UAE and Singapore launches by year-end. FY25 revenue ₹125 crore, targeting ₹200 crore.
Why this matters
Series B follows TruNativ's clean-label positioning and Tier I/II offline retail push, marking its first international expansion and a shift from D2C-only to omnichannel including pharmacy.
Retail-brand activity steady with 1,547 signals in the last 90 days.
Also reported by
- Mint — Same time